70
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Reduction of atherosclerotic lesions in rabbits treated with etoposide associated with cholesterol-rich nanoemulsions

, , &
Pages 2297-2304 | Published online: 12 Oct 2011

References

  • RossRAtherosclerosis – an inflammatory diseaseN Engl J Med199914;3402115126
  • LibbyPOkamotoYRochaVZFolcoEInflammation in atherosclerosis: transition from theory to practiceCirc J201074221322020065609
  • DzauVJBraun-DullaeusRCSeddingDGVascular proliferation and atherosclerosis: new perspectives and therapeutic strategiesNat Med20028111249125612411952
  • KolodgieFDJohnMKhuranaCFarbASustained reduction of in-stent neointimal growth with the use of a novel systemic nanoparticle paclitaxelCirculation2002106101195119812208792
  • MaranhãoRCRolandIAToffolettoOPlasma kinetic behavior in hyperlipidemic subjects of a lipidic microemulsion that binds to low density lipoprotein receptorsLipids19973266276339208392
  • RuizJKouiavskaiaDMiglioriniMThe apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptorJ Lipid Res20054681721173115863833
  • GrazianiSRIgrejaFAHeggRUptake of a cholesterol-rich emulsion by breast cancerGinecol Oncol200285493497
  • AdesACarvalhoJPGrazianiSRUptake of a cholesterol-rich emulsion by neoplasic ovarian tissuesGynecol Oncol2001811848711426966
  • MaranhãoRCGaricocheaBSilvaELPlasma kinetics and biodistribution of a lipid emulsion resembling low-density lipoprotein in patients with acute leukemiaCancer Res199454466046668062260
  • HungriaVTLatrilhaMCRodriguesDGBydlowskiSPChiattoneCSMaranhãoRCMetabolism of a cholesterol-rich microemulsion (LDE) in patients with multiple myeloma and a preliminary clinical study of LDE as a drug vehicle for treatment of the diseaseCancer Chemother Pharmacol200453516014574458
  • TeixeiraRSCuriRMaranhãoRCEffects on Walker 256 tumor of carmustine associated with a cholesterol-rich microemulsion (LDE)J Pharm Pharmacol200456790991415233870
  • Lo PreteAMariaDARodriguesDGValdugaCJIbanezOCMMaranhãoRCEvaluation in melanoma-bearing mice of an etoposide derivative associated to a cholesterol-rich nanoemulsionJ Pharm Pharmacol200658680180816734981
  • RodriguesDGMariaDAFernandesDCImprovement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studiesCancer Chemother Pharmacol200555656557615726368
  • MaranhãoRCTavaresERPadovezeAFValdugaCJRodriguesDGPereiraMDPaclitaxel associated with cholesterol-rich nanoemulsions promotes atherosclerosis regression in the rabbitAtherosclerosis2008197295996618289548
  • ZhuYBujoHYamazakiHEnhanced expression of the LDL receptor family member LR11 increases migration of smooth muscle cells in vitroCirculation2002105151830183611956127
  • PiresLAHeggRValdugaCJGrazianiSRRodriguesDGMaranhãoRCUse of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical studyCancer Chemother Pharmacol200963228128718365196
  • PinheiroKVHungriaVTFickerESValdugaCJMesquitaCHMaranhãoRCPlasma kinetics of a cholesterol-rich microemulsion (LDE) in patients with Hodgkin’s and non-Hodgkin’s lymphoma and a preliminary study on the toxicity of etoposide associated with LDECancer Chemother Pharmacol200657562463016133527
  • EngelRValkovNIGumpJLHazlehurstLDaltonWSSullivanDMThe cytoplasmic trafficking of DNA topoisomerase II alpha correlates with etoposide resistance in human myeloma cellsExp Cell Res2004295242143115093741
  • MaranhãoRCCesarTBPedroso-MarianiSRHirataMHMesquitaCHMetabolic behavior in rats of a non-protein microemulsion resembling low density lipoproteinLipids1993286916968377582
  • ValdugaCJFernandesDCLo PreteACAzevedoCHRodriguesDGMaranhãoRCUse of a cholesterol-rich microemulsion that binds to low-density lipoprotein receptors as vehicle for etoposideJ Pharm Pharmacol200355121615162214738586
  • de la Llera-MoyaMRothblatGHGlickJMEnglandJMEtoposide treatment suppresses atherosclerotic plaque development in cholesterolfed rabbitsArterioscler Thromb19921211136313701420096
  • KancherlaRRNairJSAhmedTEvaluation of topotecan and etoposide for non-Hodgkin lymphoma: correlation of topoisomerase-DNA complex formation with clinical responseCancer200191346347111169927
  • AzevedoCHCarvalhoJPValdugaCJMaranhãoRCPlasma kinetics and uptake by the tumor of a cholesterol-rich microemulsion (LDE) associated to etoposide oleate in patients with ovarian carcinomaGynecol Oncol200597117818215790455
  • Collot-TeixeiraSMartinJMcDermott-RoeCPostonRMcGregorJLCD36 and macrophages in atherosclerosisCardiovasc Res200775346847717442283
  • KleemannRZadelaarSKooistraTCytokines and atherosclerosis: a comprehensive review of studies in miceCardiovasc Res200879336037618487233
  • PerezEAMicrotubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistanceMol Cancer Ther2009882086209519671735
  • WillmanJHHoldenJAImmunohistochemical staining for DNA topoisomerase II-alpha in benign, premalignant, and malignant lesions of the prostateProstate200042428028610679757
  • BeresfordMJWilsonGDMakrisAMeasuring proliferation in breast cancer: practicalities and applicationsBreast Cancer Res20068621617164010
  • MeressePDechauxEMonneretCBertounesqueEEtoposide: discovery and medicinal chemistryCurr Med Chem200411182443246615379707